Hypoglycemic activity and mechanisms of myricetin

Qian, Junqing; Zhang, Jinqiu; Chen, Yan; Dai, Chengen; Fan, Jing; Guo, Hui

doi:10.1080/14786419.2022.2058941

Cited by 13 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High purity myricetin sample (98.1%, HPLC) was prepared by vacuum freeze drying of concentrated myricetin aqueous solution. The characterisation data obtained by liquid chromatography, nuclear magnetic resonance, and mass spectrometry were consistent with the literature (Qian et al, 2022).…”

Section: Chemicalssupporting

confidence: 88%

Antihyperlipidemic activity of myricetin

Yang,

Zhang,

Shi

et al. 2024

AAlim

View full text Add to dashboard Cite

Myricetin has been reported to have a wide variety of beneficial physiological functions. The present study investigated the antihyperlipidaemic activity of myricetin against hyperlipidaemia of high-fat diet-fed obese rats. The four-week antihyperlipidaemic activity was assayed by giving different doses of myricetin to hyperlipidaemic rats. Results showed that myricetin could reduce the harm caused by oxidative stress, decrease thiobarbituric acid reactive substances value, and decrease total cholesterol and triacylglycerol levels of hyperlipidaemic rats. Quantitative analysis of gene expression showed that myricetin's lipid-lowering activity can be activated by downregulating gene expression of fatty acid synthase (FAS) and peroxisome proliferator-activated receptor-γ (PPARγ) with upregulation of hormone-sensitive lipase (HSL) mRNA level. Thus, myricetin had significant health benefits and could be explored as a potentially promising dietary supplement for treating hyperlipidaemia.

show abstract

Section: Chemicalssupporting

confidence: 88%

Antihyperlipidemic activity of myricetin

Yang,

Zhang,

Shi

et al. 2024

AAlim

View full text Add to dashboard Cite

show abstract

“…Ellagitannins and ellagic acid derivatives as well as extracts that are rich in ellagic acid have been shown to inhibit hyperglycemia and therefore could be used as anti-diabetic nutritional supplements [ 48 ]. The good antidiabetic effect of myricetin-3-O-rhamnoside is not surprising since myricetin has been shown to have a hypoglycemic effect in STZ-induced diabetic models and also as an inhibitor of the carbohydrate digestive enzymes α-glucosidase and α-amylase [ 49 ]. Two flavonoid glycosides, myricetin-3-O-rhamnoside and quercetin-3-O-rhamnoside, have displayed the capability to inhibit carbohydrate digestive enzymes and act synergistically with α-glucosidase inhibition [ 50 ].…”

Section: Discussionmentioning

confidence: 99%

In Vitro and Molecular Docking Evaluation of the Anticholinesterase and Antidiabetic Effects of Compounds from Terminalia macroptera Guill. & Perr. (Combretaceae)

Feunaing,

Tamfu,

Gbaweng

et al. 2024

Molecules

View full text Add to dashboard Cite

Alzheimer’s disease (AD) and diabetes are non-communicable diseases with global impacts. Inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are suitable therapies for AD, while α-amylase and α-glucosidase inhibitors are employed as antidiabetic agents. Compounds were isolated from the medicinal plant Terminalia macroptera and evaluated for their AChE, BChE, α-amylase, and α-glucosidase inhibitions. From 1H and 13C NMR data, the compounds were identified as 3,3′-di-O-methyl ellagic acid (1), 3,3′,4′-tri-O-methyl ellagic acid-4-O-β-D-xylopyranoside (2), 3,3′,4′-tri-O-methyl ellagic acid-4-O-β-D-glucopyranoside (3), 3,3′-di-O-methyl ellagic acid-4-O-β-D-glucopyranoside (4), myricetin-3-O-rhamnoside (5), shikimic acid (6), arjungenin (7), terminolic acid (8), 24-deoxysericoside (9), arjunglucoside I (10), and chebuloside II (11). The derivatives of ellagic acid (1–4) showed moderate to good inhibition of cholinesterases, with the most potent being 3,3′-di-O-methyl ellagic acid, with IC50 values of 46.77 ± 0.90 µg/mL and 50.48 ± 1.10 µg/mL against AChE and BChE, respectively. The compounds exhibited potential inhibition of α-amylase and α-glucosidase, especially the phenolic compounds (1–5). Myricetin-3-O-rhamnoside had the highest α-amylase inhibition with an IC50 value of 65.17 ± 0.43 µg/mL compared to acarbose with an IC50 value of 32.25 ± 0.36 µg/mL. Two compounds, 3,3′-di-O-methyl ellagic acid (IC50 = 74.18 ± 0.29 µg/mL) and myricetin-3-O-rhamnoside (IC50 = 69.02 ± 0.65 µg/mL), were more active than the standard acarbose (IC50 = 87.70 ± 0.68 µg/mL) in the α-glucosidase assay. For α-glucosidase and α-amylase, the molecular docking results for 1–11 reveal that these compounds may fit well into the binding sites of the target enzymes, establishing stable complexes with negative binding energies in the range of −4.03 to −10.20 kcalmol−1. Though not all the compounds showed binding affinities with cholinesterases, some had negative binding energies, indicating that the inhibition was thermodynamically favorable.

show abstract

“…Various studies showed that quercetin enhances cellular glucose uptake and insulin resistance. [9] Furthermore, myricetin shows its hypoglycemic activity by reducing the body's serum glucose and insulin while increasing the expression of the insulin receptor, glucose transporter 4 (GLUT 4) gene, glucose-6-phosphatase (G-6-Pase) and Phosphoenolpyruvate Carboxykinase (PEPCK) gene. [10] Additionally, isoleucine has been found to lower blood glucose levels by increasing muscle glucose uptake and wholebody glucose oxidation while reducing hepatic gluconeogenesis.…”

Section: Ficus Religiosamentioning

confidence: 99%

Exploring the Therapeutic Potential of Herbal Plants in Managing Blood Sugar Levels: A Comprehensive Evaluation

Katrolia,

Pal,

Shukla

et al. 2023

Pharmacogn. Res.

View full text Add to dashboard Cite

Hyperglycemia, characterized by persistently high blood glucose levels due to insufficient insulin release or insulin resistance, is a major global health concern. The World Health Organization (WHO) reports a substantial increase in the number of diabetic patients, from 108 million in 1980 to 422 million in 2014, and further to 463 million in 2020. As a result, there has been a growing demand for medicinal plants to address this issue. Traditional medicine has long recognized and utilized various medicinal herbs with hypoglycemic properties. This review focuses on eight specific medicinal plants: Ficus religiosa (Moraceae), Syzygium cumini (Myrtaceae), Momordica charantia (Cucurbitaceae), Curcuma longa (Zingiberaceae), Ocimum tenuiflorum (Lamiaceae), Morinda citrifolia (Rubiaceae), Trigonella foenum-graecum Linn. (Fabaceae), and Peganum harmala (Zygophyllaceae), which have been found to play a significant role in managing hyperglycemia. The article explores the phytochemical constituents of these plants responsible for their hypoglycemic effects and elucidates their mechanisms of action. By providing a comprehensive review of these medicinal plants, this article offers valuable insights into their potential use for managing hyperglycemia.

show abstract

Hypoglycemic activity and mechanisms of myricetin

Cited by 13 publications

References 17 publications

Antihyperlipidemic activity of myricetin

Antihyperlipidemic activity of myricetin

In Vitro and Molecular Docking Evaluation of the Anticholinesterase and Antidiabetic Effects of Compounds from Terminalia macroptera Guill. & Perr. (Combretaceae)

Exploring the Therapeutic Potential of Herbal Plants in Managing Blood Sugar Levels: A Comprehensive Evaluation

Contact Info

Product

Resources

About